Ocugen Q3 net loss $20M; OCU400 Phase 3 nearing completion, Kwangdong deal signed

Ocugen, Inc.

Net loss of $20.0M ($0.07/sh) vs $13.0M ($0.05) in Q3 2024; cash $32.9M as of Sep 30 (down from $58.8M Dec 31).
OCU400 Phase 3 enrollment nearing completion; BLA filing target 1H 2026, top-line data expected 4Q 2026.
OCU410ST Phase 2/3 trial 50% enrolled; CHMP accepts single US trial for MAA; interim data mid-2026.
Signed licensing deal with Kwangdong for OCU400 in South Korea; up to $7.5M milestones plus sales milestones and 25% royalties.
Closed $20M registered direct offering; cash runway into Q2 2026; warrants exercise could add $30M and extend to 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.